Literature DB >> 23079131

Effects of topical pimecrolimus 1% on high-dose ultraviolet B-irradiated epidermal Langerhans cells.

ZhiQiang Yin1, JiaLi Xu, ZhiHong Zhang, Dan Luo.   

Abstract

Some studies reported no changes in the number of epidermal Langerhans cells (LC) that were observed in mice treated with pimecrolimus, and low-dose stimulated solar radiation (once)-induced changers in LC are minimally affected by pimecrolimus. This study is to investigate the effects of topical pimecrolimus 1% on high-dose ultraviolet B (UVB)-irradiated epidermal LC. Forty human foreskin tissues were randomly divided into 4 groups of 10 tissues each: Group A, control; Group B, pimecrolimus 1% (once)-only; Group C, 180 mJ/cm(2) UVB (once)-only; Group D, UVB+pimecrolimus. Each tissue was cut into 4 pieces corresponding to 4 time points. All the tissues were cultured at 37 °C. After being treated, the tissues were collected respectively and processed for immunohistochemical staining and immunofluorescence staining. For UVB-only group, epidermal CD1a(+) LC number at 18h decreased from 39.6 ± 8.30 to 22.3 ± 2.26/5 high magnification, compared to CD1a(+) LC number at 0 h (P<0.01). The CD1a(+) LC number of UVB-only group was significantly less than other groups at 18 h, 24h and 48 h (P<0.05, respectively). Similar results were obtained with immunofluorescence staining for CD 1a and immunohistochemical staining for Langerin. The numbers of epidermal HLA-DR(+) LC had no significant differences among all groups at different time points. Our study found a single 180 mJ/cm(2) UVB irradiation significantly reduced epidermal LC numbers at 18 h, 24h and 48 h, however, topical pimecrolimus could reverse these changes. UVB plus pimecrolimus treatment did not affect human LC maturation.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079131     DOI: 10.1016/j.intimp.2012.10.002

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  4 in total

1.  Tacrolimus Inhibits TNF-α/IL-17A-Produced pro-Inflammatory Effect on Human Keratinocytes by Regulating IκBζ.

Authors:  YingYing Hu; Jing Guo; Li Yin; Jie Tu; ZhiQiang Yin
Journal:  Inflammation       Date:  2020-04       Impact factor: 4.092

2.  Topical pimecrolimus inhibits high-dose UVB irradiation-induced epidermal Langerhans cell migration, via regulation of TNF-α and E-cadherin.

Authors:  ZhiQiang Yin; JiaLi Xu; BingRong Zhou; Di Wu; Yang Xu; JiaAn Zhang; Dan Luo
Journal:  Drug Des Devel Ther       Date:  2014-10-10       Impact factor: 4.162

3.  Ultraviolet B Inhibits IL-17A/TNF-α-Stimulated Activation of Human Dermal Fibroblasts by Decreasing the Expression of IL-17RA and IL-17RC on Fibroblasts.

Authors:  Li Yin; YingYing Hu; JiaLi Xu; Jing Guo; Jie Tu; ZhiQiang Yin
Journal:  Front Immunol       Date:  2017-02-03       Impact factor: 7.561

4.  Tacrolimus Reverses UVB Irradiation-Induced Epidermal Langerhans Cell Reduction by Inhibiting TNF-α Secretion in Keratinocytes via Regulation of NF-κB/p65.

Authors:  JiaLi Xu; YaDong Feng; GuoXin Song; QiXing Gong; Li Yin; YingYing Hu; Dan Luo; ZhiQiang Yin
Journal:  Front Pharmacol       Date:  2018-02-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.